UPDATE: Immune Repertoire Sequencing Firm Adaptive Biotechnologies Raises $5M, Aiming for $20M | GenomeWeb

The story has been updated to provide additional details and comments from Adaptive Biotechnologies' CEO, Chad Robins.

NEW YORK (GenomeWeb News) – Immune sequencing services company Adaptive Biotechnologies has raised $5 million toward a targeted $20 million financing round.

In a Form D filed with the US Securities and Exchange Commission recently, it said that the securities offered were in the form of equity. Adaptive Bio's CEO Chad Robins told GenomeWeb Daily News that that the $5 million was the first tranche of a Series C round.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.